Aviceda Therapeutics Announces Formation of European Clinical Advisory Board

Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company also announced that Tarek S. Hassan, MD will serve as Chair of the European and US CABs.

Inaugural members of the European CAB include:

Frank Holz, MD

• Professor and Chair, Department of Ophthalmology, University of Bonn, Germany
• Co-founder, German Research Foundation Priority Program for AMD & GRADE Reading Center
• Board of the German Ophthalmological Society
• Past President, EURETINA

Ursula Schmidt-Erfurth, MD

• Professor and Chair, Department of Ophthalmology and Optometry, Medical University of Vienna, Austria
• Strategical Head, Vienna Reading Center

Jordi Monés, MD, PhD

• Director, Institut de la Màcula, Barcelona, Spain
• Director, Principal Investigator and Founder of the Barcelona Macula Foundation: Research for Vision

Anat Loewenstein, MD, MHA

• President, Israeli Ophthalmology Society
• Vice Dean of the Faculty of Medicine and Sidney Fox Chair of Ophthalmology, Tel Aviv University, Israel
• Chairman, Ophthalmology Sourasky Medical Center, Tel Aviv, Israel
• President-elect, EURETINA

Usha Chakravarthy, FRCOphth, PhD, CBE

• Professor of Ophthalmology and Vision Sciences, Royal Victoria Hospital and Queens University of Belfast, Northern Ireland
• Awarded Commander of the British Empire (CBE) for services to ophthalmology

Adnan Tufail, MB, BS, MD, FRCOphth

• Professor of Ophthalmology, University College London
• Consultant Ophthalmologist, Medical Retina Service, Moorfields Eye Hospital, London, United Kingdom

“We are honored to welcome such outstanding renowned experts in clinical and academic retina to support and guide expansion of our clinical programs with AVD-104 to Europe and across the globe to bring next-generation efficacy and safety to patients with GA secondary to AMD,” Tarek S. Hassan, MD, Aviceda’s Chief Development Officer, said in a company news release.

“We are excited that results from Part 1 of the US phase 2/3 SIGLEC trial demonstrated functional and anatomic improvement in eyes with GA secondary to AMD after a single injection of AVD-104,” said Mohamed Genead, MD, Aviceda’s Co-founder and CEO. “With the contributions and support of this esteemed panel—and with Dr. Hassan as its chair—we look forward to bringing our clinical efforts to Europe later this year.”